Artiva Biotherapeutics stockholders approved 5,097,095 additional common-stock shares for the 2024 Equity Incentive Plan and added pre-funded warrants to future reserve calculations. The expanded plan is intended to help retain employees, directors and consultants while giving award recipients an opportunity to benefit from increases in common-stock value.

Key Highlights

  • Brian Daniels, M.D. And Laura Stoppel, Ph.D. Won election as Class II directors for terms extending through the 2029 annual meeting.
  • The amended plan now authorizes up to 13,328,057 shares for awards, subject to its stated adjustments and returning-share provisions.
  • Stockholders approved adding 5,097,095 shares to the 2024 Equity Incentive Plan.
  • Brian Daniels, M.D. And Laura Stoppel, Ph.D. Were elected to three-year Class II director terms.

Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) secured stockholder approval to add 5,097,095 common-stock shares to its 2024 Equity Incentive Plan and include shares issuable upon exercise of pre-funded warrants in future automatic reserve calculations. The approval came at the September 8, 2026, annual meeting, based on a July 20 Record Date when 48,885,777 shares were outstanding and entitled to vote.

Directors Elected and KPMG Appointment Ratified

Brian Daniels, M.D. Received 33,591,967 votes for, 5,774,914 votes withheld and 4,640,922 broker non-votes. Laura Stoppel, Ph.D. Received 33,862,513 votes for, 5,504,368 votes withheld and 4,640,922 broker non-votes. Both were elected to three-year Class II director terms running through the 2029 annual meeting and until successors are qualified, or earlier resignation or removal. Stockholders also ratified KPMG LLP, with 44,000,762 votes for, 4,325 against and 2,716 abstentions.

$13,328,057-Share Reserve and Future Increases

The amended plan’s total reserve is 13,328,057 shares. Its components include 823,096 shares approved at the 2026 annual meeting, 1,214,580 approved at the 2025 annual meeting, 2,630,000 initially reserved, up to 115,436 carried from the prior plan, 1,214,580 added on January 1, 2025, 1,229,777 added on January 1, 2026, 5,097,095 approved at the 2026 meeting and up to 1,826,589 returning shares. The reserve will automatically increase each January 1 from 2027 through 2034 by 5% of the applicable preceding-year share base, although the board may set a smaller increase. The plan is intended to support awards for employees, directors and consultants, including options, stock appreciation rights, restricted stock, restricted stock units and performance awards.